By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Accelrys reported after the close of the market on Monday a 70 percent jump year over year in second-quarter revenues.

For the three months ended June 30, the San Diego-based firm posted $33.7 million in revenues, up from $19.8 million a year ago. The increase was led by license and subscription revenues, which climbed to $18.6 million, a 21 percent increase, while maintenance on perpetual licenses jumped 258 percent to $8.6 million from $2.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.